Epigenetic Modulation With Oral Histone Deacetylase (HDAC) Inhibitor as a New Treatment Option in JIA

Pediatric Rheumatology - United Kingdom
doi 10.1186/1546-0096-9-s1-p166
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Histone Deacetylase (HDAC)

Science-Business eXchange
2008English

Antibody Drug Conjugates (ADC) Charged With HDAC Inhibitor for Targeted Epigenetic Modulation

Chemical Science
Chemistry
2018English

Lysophosphatidic Acid Protects Cancer Cells From Histone Deacetylase (HDAC) Inhibitor-Induced Apoptosis Through Activation of HDAC

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2008English

Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas

Laryngoscope
Otorhinolaryngology
2011English

Epigenetic Modulation With HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells

PLoS ONE
Multidisciplinary
2015English

Histone Deacetylase (HDAC) Inhibitory and Antiproliferative Activities of Phenolic-Rich Extracts Derived From the Rhizome of Hydnophytum Formicarum Jack.: Sinapinic Acid Acts as HDAC Inhibitor

BMC Complementary and Alternative Medicine
MedicineAlternative MedicineComplementary
2013English

Host Histone Acetylation Unlocks HDAC Inhibitor Potential

Oncotarget
Oncology
2017English

Histone Deacetylase 8 as a Novel Therapeutic Target in Oral Squamous Cell Carcinoma

Oncology Reports
MedicineCancer ResearchOncology
2016English

New Insights Into the Treatment of Multiple Myeloma With Histone Deacetylase Inhibitors

Current Pharmaceutical Design
Drug DiscoveryPharmacology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy